Gilead Sciences’ first quarter profit jumped 55% due to the sale of once-a-day Atripla, the only HIV med containing a regimen in a single pill, as well as Truvada. Almost 70% of the company’s profits come from HIV meds.
A Good Year for Gilead
Gilead Sciences’ first quarter profit jumped 55% due to the sale of once-a-day Atripla, the only HIV med containing a regimen in a single pill, as well as Truvada. Almost 70% of the company’s profits come from HIV meds.
POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy
POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.
Comments
Comments